TO EVALUATE THE EFFECTS OF PITAVASTATIN ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH HYPERCHOLESTEROLEMIA WHO WERE PREVIOUSLY BEING TREATED WITH ATORVASTATIN

Abstract

Objective: To evaluate the effects of Pitavastatin on glycemic control in patients with Type 2 Diabetes Mellitus with hypercholesterolemia who were previously being treated with Atorvastatin.

Study Design: The present study was a prospective and cross-over study.

Place and Duration of Study: At Combined Military Hospital Sialkot from 15th September 2018 to 15th December 2018.

Material and Methods: A total of 103 patients of Diabetes Mellitus and Hypercholesterolemia who were previously treated with Atorvastatin for at least 12 weeks were enrolled for the study. 52 patients were then switched treatment from Atorvastatin to Pitavastatin and defined as the A to P group and treated to maintain a goal of LDL-C <100 mg/dL. In the same period the rest of 51 patients were continued with Atorvastatin treatment defined as the A to A group and the dose of Atorvastatin was maintained at the same level. Serum lipid profiles and Blood Samples were obtained between 0600 hours and 900 hours after overnight fast. HbA1c levels were recorded at enrolment (baseline), and after 3 months of pitavastatin or atorvastatin treatment. HBA1c and Lipid profile were analyzed.

Results: There were no statistically significant differences in the baseline BMI, HDL-C, triglycerides or HbA1c among the two groups. Age, and duration of diabetes were significantly different among the two groups.A significant improvement in HbA1c was found in the baseline HbA1c (p=0.001) in the A to P group. At the end of the study HbA1c was lower with pitavastatin treatment than with atorvastatin treatment in A to P group.

Conclusion: Pitavastatin in comparison to Atorvastatin treatment had more favorable effects on glucose metabolism level measured as reduction in HBA1c levels in patients with type 2 Diabetes Mellitus.